| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On August 25, 2004
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1987C-0023
|
| SAFE USE OF CARBON BLACK FOR COLORING COSMETICS
|
|
|
|
|
| 2000N-1520
|
| Labeling of Menstrual Tampons: Ranges of Absorbency
|
|
|
|
|
| 2004N-0254
|
| Possible Barriers to the Availability of Medical Devices Intended to Treat or Diagnose Diseases and Conditions that Affect Children
|
|
|
|
|
| 2004N-0346
|
| Over-the-Counter Drug Products; Safety and Efficacy Review; Additional Antidiarrheal Ingredient
|
|
|
|
|
| 2004P-0231
|
| Deny approval of NDA 21-426 for Ominitrop 5.8 mg somatropin [ rDNA origin ] for injection, lyophilized powder and diluent with preservative
|
|
|
|
|
| 2004P-0379
|
| Determine whether Penthrane inhalation has been voluntarily withdrawn from sale for safety or efficacy reasons
|
|
|
|
|
| 1987C-0023
|
| SAFE USE OF CARBON BLACK FOR COLORING COSMETICS
|
|
|
| NCR
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2000N-1520
|
| Labeling of Menstrual Tampons: Ranges of Absorbency
|
|
|
|
|
| N
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004N-0254
|
| Possible Barriers to the Availability of Medical Devices Intended to Treat or Diagnose Diseases and Conditions that Affect Children
|
|
|
|
|
| C
5
|
| Cook Group Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| C
6
|
| Spina Bifida Association of America
|
| Vol #:
|
| 1
|
|
|
|
|
| C
7
|
| Texas Childres's Hospital
|
| Vol #:
|
| 1
|
|
|
|
|
| C
8
|
| American Society of Pediatric Nephrology
|
| Vol #:
|
| 1
|
|
|
|
|
| C
9
|
| American Thoracis Society (ATS)
|
| Vol #:
|
| 1
|
|
|
|
|
| C
10
|
| American Academy of Allergy Asthma & Immunology
|
| Vol #:
|
| 1
|
|
|
|
|
| C
11
|
| Advanced Medical Technology Association
|
| Vol #:
|
| 1
|
|
|
|
|
| C
12
|
| American Academy of Pediatrics
|
| Vol #:
|
| 1
|
|
|
|
|
| C
13
|
| Baylor College of Medicine
|
| Vol #:
|
| 1
|
|
|
|
|
| C
14
|
| Inamed
|
| Vol #:
|
| 1
|
|
|
|
|
| EC
9
|
| University of Florida College of Medicine
|
| Vol #:
|
| 1
|
|
|
|
|
| EC
10
Attachment
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| EC
11
Attachment
|
| American Society for Pediatric Nephrology
|
| Vol #:
|
| 1
|
|
|
|
|
| EC
12
|
| Fisher
|
| Vol #:
|
| 1
|
|
|
|
|
| EC
13
Attachment
|
| Elizabeth Glaser Pediatric AIDS Foundation
|
| Vol #:
|
| 1
|
|
|
|
|
| EMC 1
|
| Joseph T. Barr
|
| Vol #:
|
| 1
|
|
|
|
|
| EMC 2
|
| Joseph T. Barr, OD, MS
|
| Vol #:
|
| 1
|
|
|
|
|
| EMC
3
|
| American Academy of Pediatrics (AAP), Ambulatory Pediatric Assn., American Pediatri Society, et al
|
| Vol #:
|
| 1
|
|
|
|
|
| EMC
4
|
| Inamed Corporation
|
| Vol #:
|
| 1
|
|
|
|
|
| EMC
5
|
| Elizabeth Glaser Pediatric AIDS Foundation (EGPAF)
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004N-0346
|
| Over-the-Counter Drug Products; Safety and Efficacy Review; Additional Antidiarrheal Ingredient
|
|
|
|
|
| ELET
1
|
| HFD-560 to Parexel International
|
| Vol #:
|
| 1
|
|
